Companies ›Healthcare ›GRFS

GRFS — Nasdaq Diversified Pharmaceuticals

Grifols SA

$7,86

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$7,54

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Grifols SA operates in the pharmaceuticals industry, focusing on plasma-derived therapies, though specific operational details and revenue sources are not disclosed in the available data.

Business. Grifols SA (GRFS) is a diversified pharmaceuticals company headquartered in Spain. The firm operates within the Health Care sector, focusing on the development and sale of pharmaceutical products. Grifols is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments or geographic revenue mix are not provided in the available data.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY8 analysts

4 buy3 hold1 sell

Avg 12m price target11,73

Analyst recommendations

8 analysts · consensus Buy

Buy4

Hold3

Sell1

12-month price target

11,73

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

8 analysts · indicative

Ownership→

Capital Research Global Investors

largest disclosed fund holder

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning GRFS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to GRFS. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

Briefing · model-assisted

Grifols SA (GRFS) has entered the scope of this analysis for the first time, establishing a baseline for future monitoring. As this is the initial assessment for the ticker, there is no prior data available to compute material changes or deltas in performance metrics. The current snapshot serves as the foundational reference point for tracking the company's financial and operational developments moving forward. The most significant activity observed involves substantial shifts in institutional holdings as of March 31, 2026. A major modification was detected for investor ID 587, whose position fluctuated significantly, with records showing a change from 215 shares to 8,746 shares and vice versa within the reporting period. These adjustments, detected in late June 2026, highlight active trading or reporting corrections by this specific holder, marking a notable event in the company's ownership structure. In addition to the major holder adjustments, several new institutional positions were added to the top 20 holders list. Investor ID 486 established a notable position of 2,857,956 shares, valued at approximately $22.9 million, representing a weight of 0.138%. Other new entrants include investor ID 467 with 646,207 shares and investor ID 481 with 119,303 shares. These additions indicate fresh institutional interest in Grifols during the first quarter of 2026. The company's profile is currently supported by coverage from six analysts and membership in one major index, with a total of 20 top holders identified. While no cross-source signals or specific corporate events were flagged in this initial review, the influx of new institutional capital and the volatility in existing holdings suggest a period of active reassessment by investors. This baseline data will be critical for measuring future momentum and sentiment shifts for Grifols SA.

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Grifols SA (GRFS) is a diversified pharmaceuticals company headquartered in Spain. The firm operates within the Health Care sector, focusing on the development and sale of pharmaceutical products. Grifols is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments or geographic revenue mix are not provided in the available data.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

AI synthesis

GENERATED

(a) Capital structure and liquidity metrics are unavailable as the financial snapshot is missing, preventing an assessment of balance sheet strength or cash flow dynamics.

(b) Profitability and return ratios cannot be evaluated due to the absence of financial data, and no cohort median comparisons are available to benchmark performance against industry peers.

Key takeaways

Financial data is entirely unavailable, preventing any fundamental valuation or performance analysis.
Analyst sentiment is neutral with a mean recommendation of 2.50 and a uniform price target of 11.73 EUR.
Risk assessment is inconclusive due to missing financial snapshots and source documents.
Recent news indicates an allocator coverage boost, but no specific operational or strategic events are detailed.
Classification confidence is moderate at 0.78, based on rule-based classification within the Pharmaceuticals industry.
No historical growth or segment data is available to inform future outlooks.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$7,86

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

—

Revenue by segment

In Vitro Diagnostics—

low · business_description · 2026-07-03

Plasma Derivatives—

low · business_description · 2026-07-03

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison7 peers · vs GRFS · multiples and returns

MCK—

Mckesson Corp

$827,14

102,6B USD

P/E

21,2x

— vs self

Div yield

0,4 %

— vs self

ROE

-219,2 %

— vs self

COR—

Cencora Inc

$308,37

60,2B USD

P/E

36,4x

— vs self

Div yield

0,8 %

— vs self

ROE

45,7 %

— vs self

CAH—

Cardinal Health Inc

$235,60

57,0B USD

P/E

36,7x

— vs self

Div yield

0,9 %

— vs self

ROE

-55,9 %

— vs self

DB—

DB.V

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

REGN—

REGENERON PHARMACEUTICALS, INC.

$757,99

81,0B USD

P/E

15,5x

— vs self

Div yield

—

— vs self

ROE

14,2 %

— vs self

BIIB—

BIOGEN INC.

$201,74

29,6B USD

P/E

21,3x

— vs self

Div yield

—

— vs self

ROE

7,5 %

— vs self

ZTS—

Zoetis Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 43 %

EPS

Consensus EPS

0,94

Predicted surprise

-0,08

Beat probability

43 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

revision ratio -0,04 · as of 2026-07-25 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,94
Revenue	—no estimate	—no estimate	7,7B EUR
Operating income	—no estimate	—no estimate	1,5B EUR

Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 3 %

Probability

3 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-22 · 1,0× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution8 analysts

Strong buy1

Buy3

Hold3

Sell1

Strong sell0

12-month price target$11,73 · Median $11,73

Low $11,73High $11,73

Operating income · consensus1,5B EUR

EPS surprise

−22,4 %

reported vs consensus · miss

Revenue surprise

−2,2 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$11,73

Mean$11,73

Median$11,73

High$11,73

Spot$7,86

+49.2 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskUnknown

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

M&A probabilityconf —

Probability

3 %

Base rate

3 %

Band

Low

180-day horizon · target 2027-01-22 · 1,0× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Market Price
input from market-data provider (delayed close or quote-shim mid)

Source documents

Grifols SA company facts · 2026-07-25
allocator_boost (allocator) on GRFS · 2026-07-25
Grifols SA Market data — analyst estimates · 2026-07-25
Grifols SA Market data — ESG · 2026-07-25
Grifols SA HA canonical relationships · 2026-07-25

Ownership & reference

Top holders

Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,03 %$184M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,01 %$26M
Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,01 %$22M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$25M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$8M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$11M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$23M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$2M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$14M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$5M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$1M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Leadership

Nacho Abia BuenacheChief Executive Officer, Executive Director

Insider activity

— missing data

Short positioning

6.3Mshares short+3.7% vs prior

8.17days to cover

64.0%short of daily vol

5.2Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Index membership

IBEX 35

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

GRFSCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob43 %Surprise-0,08M&A prob3 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskUnknown

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-08-03EVENTQ2 2026 earnings (expected) estimated date

2026-07-27EVENTQ2 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-27 03:14 UTCHOLDERInstitutional holding changed

2026-06-27 03:14 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-21 02:57 UTCHOLDERInstitutional holding changed

2026-06-21 02:57 UTCHOLDER18 institutional position changes flagged (1 major)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-18FILINGFORM 6-K →

2026-05-15FILINGFORM 6-K →

2026-05-07FILINGFORM 6-K →

2026-04-17FILINGFORM 20-F →

2026-04-14FILINGFORM 6-K →

2026-03-24FILINGFORM 6-K →

2026-02-26FILINGFORM 6-K →

2026-01-08FILINGFORM 6-K →

2025-12-16FILINGFORM 6-K →

2025-11-04FILINGFORM 6-K →

2025-09-29FILINGFORM 6-K →

2016-04-21 00:00 UTCINSIDER1 insider transaction — 2016-04 1 derivative

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread